ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

9.060 -0.060 (-0.66%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist

Price and Volume

Volume	1,528,054
Open	8.860
Bid (Size)	8.500 (100)
Ask (Size)	9.130 (500)
Prev. Close	9.120
Today's Range	8.700 - 9.120
52wk Range	6.660 - 18.90
Shares Outstanding	95,568,307
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

February 23, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗

February 16, 2026

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Via The Motley Fool

Performance

YTD	-21.1%	-21.1%
1 Month	-6.3%	-6.3%
3 Month	-9.4%	-9.4%
6 Month	-15.3%	-15.3%
1 Year	-16.5%	-16.5%

More News

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

February 10, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Outlook For ARS Pharmaceuticals ↗

November 07, 2025

Via Benzinga

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

February 02, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

January 21, 2026

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

December 29, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

November 26, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗

November 10, 2025

Via The Motley Fool

ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗

November 10, 2025

Via Chartmill

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

November 10, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

November 04, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

November 03, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

November 03, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

November 03, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

October 08, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 03, 2025

Via Benzinga

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

September 29, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗

September 23, 2025

Via Benzinga

neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

September 19, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

September 08, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

August 28, 2025

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharma Sales Jump 3,040% in Q2 ↗

August 13, 2025

Via The Motley Fool

ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists ↗

August 13, 2025

Via Chartmill

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?

ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market

What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?

The current price of ARS Pharmaceuticals, Inc. - Common Stock is 9.060

When was ARS Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 03/06/26 04:00 PM ET

What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?

The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 865.85M

How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?

ARS Pharmaceuticals, Inc. - Common Stock has 866M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.